Structure Therapeutics Inc. (GPCR)
NASDAQ: GPCR · IEX Real-Time Price · USD
39.89
+0.90 (2.31%)
May 3, 2024, 11:39 AM EDT - Market open
Structure Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
93
Market Cap
1.86B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 0 | - | - |
| Dec 31, 2022 | 0 | - | - |
| Dec 31, 2021 | 0 | - | - |
| Dec 31, 2020 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGPCR News
- 16 days ago - Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates. - Market Watch
- 7 weeks ago - Wegovy and Zepbound Are King. Who's Coming for Their Crowns. - Barrons
- 7 weeks ago - Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference - GlobeNewsWire
- 2 months ago - Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights - GlobeNewsWire
- 3 months ago - The weight loss drug market may soon get more crowded – here are the companies trying to enter the booming space - CNBC
- 4 months ago - Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk? - Market Watch
- 4 months ago - Structure Therapeutics reports promising results for weight-loss pill - Invezz
- 4 months ago - New Shakeup Hits Obesity Pills. Structure Rolls Out Disappointing Data. - Barrons